Total pharma industry venture financing deals in April 2019 worth $1.55bn were announced globally, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked an increase of 30.1% over the previous month and a drop of 12.2% when compared with the last 12-month average, which stood at $1.77bn.
Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $1.13bn. At the country level, the US topped the list in terms of deal value at $1.05bn.
In terms of volumes, North America emerged as the top region for pharma industry venture financing deals globally, followed by Asia-Pacific and then Europe.
The top country in terms of venture financing deals activity in April 2019 was the US with 58 deals, followed by China with seven and Israel with two.
In 2019, as of the end of April 2019, pharma venture financing deals worth $6.51bn were announced globally, marking a decrease of 18.4% year on year.
Pharma industry venture financing deals in April 2019: Top deals
The top five pharma industry venture financing deals accounted for 45.1% of the overall value during April 2019.
The combined value of the top five pharma industry venture financing deals stood at $699m, against the overall value of $1.55bn recorded for the month. The top announced pharma industry venture financing deal tracked by GlobalData in April 2019 was Country Garden Holdings, Sequoia Capital China and Tencent Holdings’ $250m venture financing of Tencent Trusted Doctors.
In second place was the $142m venture financing of Poseida Therapeutics by Aisling Capital, Boxer Capital, Longitude Capital Management Co, Malin Corporation, Novartis Pharma, Pentwater Capital Management, Perceptive Advisors and Vivo Capital and in third place was ArrowMark Partners, Bain Capital, Boxer Capital, BVF Partners, GlaxoSmithKline, HBM Healthcare Investments, LifeArc, Orbimed Advisors, Perceptive Advisors, Pfizer Venture Investments, Samsara BioCapital and Surveyor Capital’s $125m venture financing of SpringWorks Therapeutics.
The $100m venture financing of Talaris Therapeutics by Blackstone Life Sciences, Longitude Capital Management Co and Qiming Venture Partners USA and Alexandria Venture Investments, Altitude Life Science Ventures, ARCH Venture Partners, BVF Partners, Cardinal Partners, Casdin Capital, Celgene, Mirae Asset Capital, Mubadala Ventures, Nextech Invest, Trinitas Capital Management and Versant Venture Management’s venture financing of Vividion Therapeutics for $82m held fourth and fifth positions, respectively.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.
